Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

Investigational New Drugs
Toshiyuki SawaY Ariyoshi

Abstract

Amrubicin is a novel 9-aminoanthracycline. This multicenter phase II study was conducted to evaluate the efficacy and safety of amrubicin in patients with non-small-cell lung cancer (NSCLC). Sixty-one previously untreated patients with stage III or IV NSCLC were entered this study. The patients were required to have cytologically or histologically proven measurable NSCLC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and adequate organ function. Amrubicin was administered by daily intravenous injection at 45 mg/m2/day for 3 consecutive days every 3 weeks. At least 3 cycles of treatment were administered to each patient. All 61 patients registered in this trial were eligible and assessable for efficacy and toxicity. Of them, 17 patients achieved objective responses, consisting of one complete response and 16 partial responses, and the overall response rate was 27.9% (95% confidence interval [CI], 17.1% to 40.8%). The median survival time was 9.8 months (95% CI, 7.7 months to 14.9 months). The major toxicity was myelosuppression. The incidences of grade 3 or 4 toxicity were 72.1% for neutropenia, 52.5% for leukopenia, 23.0% for anemia, and 14.8% for thrombocytopenia. As noticeable toxic events, grade 3 h...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R FeldM Lassus
Mar 1, 1992·British Journal of Cancer·E F SmitP E Postmus
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E F SmitP E Postmus
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MartoniF Pannuti
Jan 1, 1989·Japanese Journal of Cancer Research : Gann·S MorisadaM Fukui
Sep 1, 1974·Cancer·E P CortesJ F Holland
Apr 1, 1984·European Journal of Cancer & Clinical Oncology·R A JossM Rozencweig
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R GrilliJ A Julian
Dec 16, 1998·Japanese Journal of Cancer Research : Gann·T NoguchiY Yanagi
Jan 23, 1999·Japanese Journal of Cancer Research : Gann·M HanadaT Yamaoka

❮ Previous
Next ❯

Citations

May 9, 2008·International Journal of Clinical Oncology·Manabu KatouYoshiki Sugimura
May 14, 2010·International Journal of Clinical Oncology·Satoshi IgawaNoriyuki Masuda
Jul 14, 2007·Investigational New Drugs·Takayasu KurataMasahiro Fukuoka
Jun 4, 2011·Japanese Journal of Clinical Oncology·Hiroshi YoshidaTomohide Tamura
Oct 20, 2012·Japanese Journal of Clinical Oncology·Reiko Ando MakiharaHiroshi Yamamoto
Oct 16, 2009·Expert Review of Anticancer Therapy·Michaela J Higgins, David S Ettinger
May 12, 2007·Expert Review of Anticancer Therapy·Roberta FerraldeschiPaul Lorigan
Feb 26, 2009·Expert Opinion on Drug Metabolism & Toxicology·Takayasu Kurata
Aug 5, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kiyotaka YohYutaka Nishiwaki
Nov 4, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hiroyasu KanedaUNKNOWN West Japan Thoracic Oncology Group
Oct 27, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kyoichi KairaMasatomo Mori
Mar 8, 2016·Asia-Pacific Journal of Clinical Oncology·Yoshinori MakinoYoshikazu Hayashi
Feb 28, 2007·Trends in Molecular Medicine·Christine L Hann, Charles M Rudin
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sayaka OnodaUNKNOWN Thoracic Oncology Research Group Study 0301
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H YoshiokaK Nakagawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.